Otsuka Pharmaceutical Co., Ltd.
MIREVO®, a New Cognitive Function Testing Application for Dementia Care Support,
Obtains Regulatory Approval, a First in Japan
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that Ai-BrainScience Inc. (Ai-Brain Science) has received manufacturing and marketing approval in Japan for MIREVO®, a new cognitive function testing application that uses eye-tracking technology. This program is the first in Japan to receive regulatory approval for use in dementia care support. Otsuka and Ai-BrainScience will proceed with procedures for health insurance coverage and launch the program as soon as preparations are complete.
By using the app MIREVO® installed from an app store on a tablet device, the test can be done in approximately three minutes. When the person under assessment views contents displayed on the screen and selects the answers, the data are automatically scored. This enables an initial, and then periodic, cognitive function evaluation to be done objectively and quantitatively by staff who might not possess the knowledge and experience of a specialist.